Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohide Tamura

Showing results (41-50 of 263) with videos related to

Pageof 27
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell linesYoshiko Kawamura-Akiyama, Hitoshi Kusaba, Fumihiko Kanzawa, et al.
The Biochemical Journal|April 21, 2006
In-frame deletion in the EGF receptor alters kinase inhibition by gefitinibKazuko Sakai, Hideyuki Yokote, Kimiko Murakami-Murofushi, et al.
Internal Medicine (Tokyo, Japan)|September 14, 2018
Yellow Nail Syndrome Patients with Diffuse Panbronchiolitis-like Pulmonary ManifestationRyosuke Imai, Ryo Nakatani, Hiroshi Nakaoka, et al.
Cancer Science|June 29, 2007
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicityIkuo Sekine, Kazuhiko Yamada, Hiroshi Nokihara, et al.
International Journal of Cancer|October 19, 2013
KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cellsYusuke Nakadate, Yasuo Kodera, Yuka Kitamura, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsHaruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, et al.
The Tohoku Journal of Experimental Medicine|September 6, 2007
Problems with registration-directed clinical trials for lung cancer in JapanIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancerHideharu Kimura, Kazuo Kasahara, Makoto Kawaishi, et al.
Japanese Journal of Clinical Oncology|March 6, 2009
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumorsNoboru Yamamoto, Yasuhide Yamada, Yutaka Fujiwara, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2014
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumorsHiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, et al.
Pageof 27

Showing results (41-50 of 263) with videos related to

Sort By:
Pageof 27
Lung Cancer (Amsterdam, Netherlands)|October 9, 2002
Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell linesYoshiko Kawamura-Akiyama, Hitoshi Kusaba, Fumihiko Kanzawa, et al.
The Biochemical Journal|April 21, 2006
In-frame deletion in the EGF receptor alters kinase inhibition by gefitinibKazuko Sakai, Hideyuki Yokote, Kimiko Murakami-Murofushi, et al.
Internal Medicine (Tokyo, Japan)|September 14, 2018
Yellow Nail Syndrome Patients with Diffuse Panbronchiolitis-like Pulmonary ManifestationRyosuke Imai, Ryo Nakatani, Hiroshi Nakaoka, et al.
Cancer Science|June 29, 2007
Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicityIkuo Sekine, Kazuhiko Yamada, Hiroshi Nokihara, et al.
International Journal of Cancer|October 19, 2013
KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cellsYusuke Nakadate, Yasuo Kodera, Yuka Kitamura, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumorsHaruyasu Murakami, Yutaka Ueda, Tatsu Shimoyama, et al.
The Tohoku Journal of Experimental Medicine|September 6, 2007
Problems with registration-directed clinical trials for lung cancer in JapanIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancerHideharu Kimura, Kazuo Kasahara, Makoto Kawaishi, et al.
Japanese Journal of Clinical Oncology|March 6, 2009
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumorsNoboru Yamamoto, Yasuhide Yamada, Yutaka Fujiwara, et al.
Cancer Chemotherapy and Pharmacology|January 21, 2014
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumorsHiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, et al.
Pageof 27